The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a comb...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
EPIXCHANGE
Innovative gene therapies for epilepsy treatment
1M€
Cerrado
SAF2010-17589
ESTUDIOS SOBRE ENFERMEDADES LISOSOMALES: BASES MOLECULARES,...
18K€
Cerrado
RTC-2016-5686-1
Desarrollo de tratamientos para enfermedades raras de depósi...
323K€
Cerrado
Treat-HSP
Development of new therapy for rare motor neuron diseases
150K€
Cerrado
SAF2009-11289
INVESTIGACION SOBRE LAS CAUSAS MOLECULARES Y ESTRATEGIAS TER...
48K€
Cerrado
SAF2014-56562-R
IDENTIFICACION DE VARIANTES, GENERACION DE MODELOS Y ENSAYOS...
121K€
Cerrado
Información proyecto BATCure
Duración del proyecto: 42 meses
Fecha Inicio: 2015-12-04
Fecha Fin: 2019-06-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a combined incidence of c.1:100 000. The NCLs are devastating and debilitating genetic disorders that mainly affect children, who suffer progressive dementia and motor decline, visual failure and epilepsy, leading to a long period of complete dependence on others, and eventually a premature death. Existing palliative treatment can reduce, but does not eliminate, the burden of seizures and the progressively worsening effects on the whole body due to decreasing CNS influence and control. There are no curative treatments in the clinic for any type of NCL. We will follow a novel integrated strategy to identify specific gene and small molecule treatments for three genetic types of Batten disease that include the most prevalent world-wide, juvenile CLN3 disease, and in southern and mediterranean Europe, CLN6 and CLN7 diseases.
To develop new therapies for these 3 types of Batten disease, BATCure will:
1. Create new models, tools and technologies for developing and testing therapies
2. Further delineate disease biology and gene function to identify new therapeutic target pathways utilising yeast and pluripotent stem cell models
3. Identify biochemical therapeutic target pathways, facilitate effective evaluation of preclinical therapies and improve diagnostics
4. Extend a comprehensive natural history beyond the brain to include cardiology, the spinal cord, PNS, psychiatric and metabolic changes
5. Identify new and repurpose existing small molecule therapy
6. Triage new compound treatments in zebrafish, a high-throughput small vertebrate model
7. Deliver and monitor new treatments using mouse models
8. Provide a novel mechanism to involve patients and their families to inform and fully contribute to therapy development and prepare for clinical trials